Prognostic factors for patients treated with abiraterone

Area of Science:

• Oncology
• Urology
• Clinical Research

Background:

• Metastatic castration-resistant prostate cancer (mCRPC) is an advanced stage of prostate cancer.
• Abiraterone acetate (AA) is a standard treatment for mCRPC.
• Identifying prognostic factors is crucial for treatment management.

Purpose of the Study:

• To evaluate prostate-specific antigen response (PSAr) as a prognostic factor.
• To assess PSAr in patients with mCRPC receiving abiraterone acetate (AA).
• Define PSAr as a ≥50% decrease in PSA concentration from baseline.

Main Methods:

• Retrospective analysis of mCRPC patients treated with AA.
• Evaluation of prostate-specific antigen (PSA) levels.
• Statistical analysis including multivariate analysis.

Main Results:

• 124 patients were included in the study.
• Patients achieving PSAr had significantly longer median overall survival (29.3 vs 9.7 months) and progression-free survival (17.0 vs 5.2 months).
• Multivariate analysis confirmed PSAr as a significant predictor of improved survival (OS HR: 0.19; PFS HR: 0.24).

Conclusions:

• Prostate-specific antigen response (PSAr) is a valuable prognostic factor for mCRPC patients on abiraterone acetate.
• PSAr can serve as a predictive factor for treatment outcomes.
• This finding aids in patient stratification and treatment monitoring.